SCHEMBL9944151

SCHEMBL9944151

CCOc1c(C)cc(C(=O)Nc2ccc(C(=O)O)c(F)c2)cc1Br

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.53
MEN1 O00255 6/20 0.53
KMT2A Q03164 6/20 0.53
SMN1; SMN2 Q16637 6/20 0.50
ALDH1A1 P00352 4/20 0.50
LMNA P02545 2/20 0.50
GAA P10253 2/20 0.50
RARA P10276 2/20 0.46
RARB P10826 2/20 0.46
RARG P13631 1/20 0.46
RAB9A P51151 3/20 0.45
NPC1 O15118 3/20 0.45
P4HTM Q9NXG6 2/20 0.44
ABL1 P00519 1/20 0.43
HPGD P15428 1/20 0.43
RIN1 Q13671 1/20 0.43
TP53 P04637 2/20 0.42
KDM4E B2RXH2 2/20 0.42
POLB P06746 1/20 0.42
PTGFR P43088 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9944207 0.93 KMT2A (0.53) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL9944150 0.90 MAPT (0.54) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL9944148 0.87 RAB9A (0.58) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL1458118 0.87 MAPT (0.50) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL1458178 0.85 MAPT (0.56) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL9944208 0.84 MAPT (0.52) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL9944137 0.84 MAPT (0.60) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL9944100 0.83 RARA (0.52) MAPTMEN1KMT2ASMN1; SMN2RARA
SCHEMBL1457720 0.82 MEN1 (0.66) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL1457726 0.81 MAPT (0.54) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9447028-B2 Therapeutic aryl-amido-aryl compounds and their use KING'S COLLEGE LONDON (GB) 2016-09-20 US disclosed
US-20160039747-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2016-02-11 US disclosed
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG MAPT 150/4885MEN1 4809/4885KMT2A 1418/4885
US-20160039747-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG MAPT 150/4885MEN1 4809/4885KMT2A 1418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.